Verve Therapeutics
About Us
Why Cardiovascular Disease
Our Approach
Our Pipeline
Culture & Careers
Investors
Overview
News & Events
Presentations
Stock Information
Corporate Governance
Financials & Filings
IR Resources
With durable monkey data, Verve selects its first CRISPR base editing treatment for human trials
Post navigation
Previous Post
Previous
Looking to leapfrog antibodies and RNAi, Sekar Kathiresan says gene editing approach to cut PCSK9 looks durable
Next Post
Next
Why Verve chose base editing over standard CRISPR for its lead CV candidate
Home
About Us
Why Cardiovascular Disease
Our Approach
Our Pipeline
Culture & Careers
Investors
►
◄ Back
Overview
News & Events
Stock Information
Corporate Governance
Financials & Filings
IR Resources
Contact Us